Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Hereditary factors play a key role in the risk of developing several cancers. Identification of a germline predisposition can have important implications for treatment decisions, risk-reducing interventions, cancer screening, and germline testing. OBJECTIVE: To examine the prevalence of pathogenic germline variants (PGVs) in patients with cancer using a universal testing approach compared with targeted testing based on clinical guidelines and the uptake of cascade family variant testing (FVT). DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter cohort study assessed germline genetic alterations among patients with solid tumor cancer receiving care at Mayo Clinic cancer centers and a community practice between April 1, 2018, and March 31, 2020. Patients were not selected based on cancer type, disease stage, family history of cancer, ethnicity, or age. EXPOSURES: Germline sequencing using a greater than 80-gene next-generation sequencing platform. MAIN OUTCOMES AND MEASURES: Proportion of PGVs detected with a universal strategy compared with a guideline-directed approach and uptake of cascade FVT in families. RESULTS: A total of 2984 patients (mean [SD] age, 61.4 [12.2] years; 1582 [53.0%] male) were studied. Pathogenic germline variants were found in 397 patients (13.3%), including 282 moderate- and high-penetrance cancer susceptibility genes. Variants of uncertain significance were found in 1415 patients (47.4%). A total of 192 patients (6.4%) had incremental clinically actionable findings that would not have been detected by phenotype or family history-based testing criteria. Of those with a high-penetrance PGV, 42 patients (28.2%) had modifications in their treatment based on the finding. Only younger age of diagnosis was associated with presence of PGV. Only 70 patients (17.6%) with PGVs had family members undergoing no-cost cascade FVT. CONCLUSIONS AND RELEVANCE: This prospective, multicenter cohort study found that universal multigene panel testing among patients with solid tumor cancer was associated with an increased detection of heritable variants over the predicted yield of targeted testing based on guidelines. Nearly 30% of patients with high-penetrance variants had modifications in their treatment. Uptake of cascade FVT was low despite being offered at no cost.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
The Missing Diversity in Human Genetic Studies
Sirugo, G., Williams, S. M., & Tishkoff, S. A. (2019) · Cell · doi:10.1016/j.cell.2019.02.048 · Cited by 1,516
Prostate Cancer, Version 1.2016
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., D'Amico, A. V., Davis, B. J., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0004 · Cited by 653
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
Self-citationHampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
Yurgelun, M. B., Kulke, M. H., Fuchs, C. S., Allen, B. A., Uno, H., Hornick, J. L., Ukaegbu, C. I., Brais, L. K., McNamara, P. G., Mayer, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0012 · Cited by 524
Mandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511
Daly, M. B., Pilarski, R., Yurgelun, M. B., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Garber, J. E., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0017 · Cited by 505
Self-citationClinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6607 · Cited by 485
Nicolosi, P., Ledet, E., Yang, S., Michalski, S., Freschi, B., O’Leary, E., Esplin, E. D., Nussbaum, R. L., & Sartor, O. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6760 · Cited by 365
Self-citationUnderdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Beitsch, P. D., Whitworth, P. W., Hughes, K., Patel, R., Rosen, B., Compagnoni, G., Baron, P., Simmons, R., Smith, L. A., Grady, I., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01631 · Cited by 363
Self-citationDesmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., Yang, S., Shannon, K. M., Tung, N., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2690 · Cited by 333
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Gupta, S., Provenzale, D., Llor, X., Halverson, A. L., Grady, W., Chung, D. C., Haraldsdottir, S., Markowitz, A. J., Slavin Jr, T. P., Hampel, H., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0044 · Cited by 331
The Missing Diversity in Human Genetic Studies
Sirugo, G., Williams, S. M., & Tishkoff, S. A. (2019) · Cell · doi:10.1016/j.cell.2019.04.032 · Cited by 314
Mvundura, M., Grosse, S. D., Hampel, H., & Palomaki, G. E. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd666c · Cited by 292
Kurian, A. W., Li, Y., Hamilton, A. S., Ward, K. C., Hawley, S. T., Morrow, M., McLeod, M. C., Jagsi, R., & Katz, S. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6480 · Cited by 265
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy024 · Cited by 224
Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk
Caswell-Jin, J. L., Gupta, T., Hall, E., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R., Chun, N. M., Levonian, P., Lebensohn, A. P., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.96 · Cited by 208
Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing
Knowles, J. W., Rader, D. J., & Khoury, M. J. (2017) · JAMA · doi:10.1001/jama.2017.8543 · Cited by 190
Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature
Roberts, M. C., Dotson, W. D., DeVore, C. S., Bednar, E. M., Bowen, D. J., Ganiats, T. G., Green, R. F., Hurst, G. M., Philp, A. R., Ricker, C. N., et al. (2018) · Health Affairs · doi:10.1377/hlthaff.2017.1630 · Cited by 190
Carlo, M. I., Mukherjee, S., Mandelker, D., Vijai, J., Kemel, Y., Zhang, L., Knezevic, A., Patil, S., Ceyhan-Birsoy, O., Huang, K.-C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1986 · Cited by 187
Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative
Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., & Kurian, A. W. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy147 · Cited by 130
Ndugga-Kabuye, M. K., & Issaka, R. B. (2019) · Familial Cancer · doi:10.1007/s10689-019-00144-6 · Cited by 111
Neben, C. L., Zimmer, A. D., Stedden, W., van den Akker, J., O'Connor, R., Chan, R. C., Chen, E. Y., Tan, Z., Leon, A., Ji, J., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.03.001 · Cited by 108
Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma
Brand, R. E., Borazanci, E. H., Speare, V., Dudley, B., Karloski, E., Peters, M. L. B., Stobie, L., Bahary, N., Zeh, H. J., Zureikat, A. H., et al. (2018) · Cancer · doi:10.1002/cncr.31628 · Cited by 97
Samimi, G., Bernardini, M. Q., Brody, L. C., Caga-Anan, C., Campbell, I., Chenevix‐Trench, G., Couch, F. J., Dean, M. C., de Hullu, J. A., Domchek, S. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3439 · Cited by 91
Ricker, C. N., Culver, J. O., Lowstuter, K. J., et al. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2015.12.013 · Cited by 84
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
Eccleston, A., Bentley, A., Dyer, M., Strydom, A., Vereecken, W., George, A. J., & Rahman, N. (2017) · Value in Health · doi:10.1016/j.jval.2017.01.004 · Cited by 81
Rosenthal, E. T., Bernhisel, R., Brown, K. L., Kidd, J., & Manley, S. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.09.003 · Cited by 81
Hereditary Cancer Syndromes—A Primer on Diagnosis and Management
Samadder, N. J., Giridhar, K. V., Baffy, N. J., Riegert‐Johnson, D. L., & Couch, F. J. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.02.017 · Cited by 75
Self-citationGriffin, N. E., Buchanan, T., Smith, S. H., Leon, A. A., Meyer, M. F., Liu, J., Tabak, R. G., Fuh, K. C., Thaker, P. H., Powell, M. A., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.005 · Cited by 58
Pal, T., Cragun, D., Lewis, C., Doty, A., Rodriguez, M., Radford, C., Thompson, Z., Kim, J., & Vadaparampil, S. T. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0381 · Cited by 56
Idos, G., Kurian, A. W., Ricker, C. N., Sturgeon, D., Culver, J. O., Kingham, K. E., Koff, R., Chun, N. M., Rowe‐Teeter, C., Lebensohn, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00217 · Cited by 56
Impact of free cancer predisposition cascade genetic testing on uptake in Singapore
Courtney, E., Chok, A. K.-L., Ang, Z. L. T., Shaw, T., Li, S.-T., Yuen, J., & Ngeow, J. Y. Y. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0096-5 · Cited by 56
Samadder, N. J., Baffy, N. J., Giridhar, K. V., Couch, F. J., & Riegert‐Johnson, D. L. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.042 · Cited by 55
Self-citationKurian, A. W., Friese, C. R., Bondarenko, I., Jagsi, R., Li, Y., Hamilton, A. S., Ward, K. C., & Katz, S. J. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5652 · Cited by 31
When Should Patients Undergo Genetic Testing for Hereditary Colon Cancer Syndromes?
Idos, G., & Gupta, S. N. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.11.010 · Cited by 8
Cited by
Increasing Incidence of Early-Onset Colorectal Cancer
Sinicrope, F. A. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2200869 · Cited by 534
Metadata
- Authors
- Samadder, N. J., Riegert-Johnson, D., Boardman, L., Rhodes, D., Wick, M., Okuno, S., Kunze, K. L., Golafshar, M., Uson, P. L. S., Mountjoy, L., Ertz-Archambault, N., Patel, N., Rodriguez, E. A., Lizaola-Mayo, B., Lehrer, M., Thorpe, C. S., Yu, N. Y., Esplin, E. D., Nussbaum, R. L., Sharp, R. R., Azevedo, C., Klint, M., Hager, M., Macklin-Mantia, S., Bryce, A. H., Bekaii-Saab, T. S., Sekulic, A., & Stewart, A. K.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-02-01
- Volume
- 7
- Issue
- 2
- Pages
- 230
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3095016275
- Cited by
- 304
- References
- 38
- FWCI
- 19.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.